Norwegian life sciences company ArcticZymes Technologies ASA (OSE:AZT) said on Monday that it has expanded its GMP product portfolio with the launch of M-SAN HQ GMP, a nuclease designed specifically for next-generation viral vector manufacturing.

The product offers the enzymatic performance of M-SAN HQ, combined with the regulatory compliance of GMP-grade production.

M-SAN HQ GMP operates effectively at physiological salt concentrations (~150 mM), enabling direct application in cell culture media or harvest supernatants without the need for buffer exchanges. This makes it particularly suited for manufacturing fragile viral vectors such as lentiviruses and retroviruses, which are integral to advanced therapies and vaccine development.

The product supports a seamless transition from development to full-scale production for viral vector manufacturers. Its release addresses the increasing demand for DNA clearance in novel therapeutic modalities, including in vivo CAR-T therapies.

M-SAN HQ GMP enhances ArcticZymes Technologies' position as a solutions provider in biomanufacturing and cell and gene therapy workflows.